The t(10;11)(p12;q14) is a recurring chromosomal translocation that gives rise to the CALM/AF10 fusion gene, which is found in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma. We analyzed the fusion transcripts in 20 new cases of CALM/AF10-positive leukemias, and compared the gene expression profile of 10 of these to 125 patients with other types of leukemia and 10 normal bone marrow samples. Based on gene set enrichment analyses, the CALM/AF10-positive samples showed significant upregulation of genes involved in chromatin assembly and maintenance and DNA repair process, and downregulation of angiogenesis and cell communication genes. Interestingly, we observed a striking upregulation of four genes located immediately centromeric to the break point of the t(10;11)(p12;q14) on 10p12 (COMMD3 (COMM domain containing 3), BMI1 (B lymphoma Mo-MLV insertion region 1 homolog), DNAJC1 (DnaJ (Hsp40) homolog subfamily C member 1) and SPAG6 (sperm associated antigen 6)). We also conducted semiquantitative reverse transcriptase-PCR analysis on leukemic blasts from a murine CALM/AF10 transplantation model that does not have the translocation. Commd3, Bmi1 and Dnajc1, but not Spag6 were upregulated in these samples. These results strongly indicate that the differential regulation of these three genes is not due to the break point effect but as a consequence of the CALM/AF10 fusion gene expression, though the mechanism of regulation is not well understood.
INTRODUCTION
The t(10;11)(p12;q14) is a recurring chromosomal translocation that is found in acute myeloid (AML) and acute lymphoblastic leukemia (ALL), as well as in malignant lymphoma. 1, 2 This translocation results in the fusion of AF10, 3 a putative zinc finger transcription factor, and CALM (Clathrin assembly protein lymphoid myeloid leukemia) gene that encodes a clathrin assembly protein. 1 The AF10 protein has several functional domains. It contains a protein --protein interaction motif comprising the extended LAP/ PHD-finger domain (LAP: leukemia associated protein; PHD: plant homeo domain) that mediates homo-oligomerization. This domain is conserved in several proteins, including MLL. 4 ,5 AF10 binds cruciform DNA via a specific interaction with an AT-hook motif and is localized to the nucleus by a bipartite nuclear localization signal in the N-terminal region. 4 AF10 also has an octapeptide motif and leucine zipper domain (OM/LZ), which has been shown to mediate interaction with IKZF1 6 and the protein encoded by the histone H3 methyltransferase gene DOT1L. 7 PHDs, which are present in the N-terminus of AF10, have also been shown to bind to various histone modifications. For instance, PHDs bind to H3K4me3 modifications, 8, 9 which are chromatin modifications usually found in the promoters of transcriptionally active genes.
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AF10 is one of more than 30 MLL fusion partners in leukemia. 11 CALM , also known as PICALM, is located on chromosome 11q23, is ubiquitously expressed and encodes a 652 amino-acid protein with multiple domains having a role in endocytosis. 1 These domains include the epsin N-terminal homology domain, a DPF (ASP-Pro-Phe) motif, an NPF (Asn-Pro-Phe) motif and type I and II clathrin-binding sequences. 12 --14 The CALM protein is similar to the neuronal specific monomeric clathrin assembly protein AP180, which was first identified in coated vesicles of bovine brain. 15, 16 The CALM/AF10 fusion protein contains almost the complete CALM protein fused to about 90% of the AF10 protein without the two N-terminal PHD zinc fingers 1 ( Figure 1 ). In the monocytic cell line U937, both the CALM/AF10 and the AF10/CALM fusion mRNAs can be identified. 1 In a study of a series of nine leukemia patients with a t(10;11) Carlson and co-workers identified four different CALM/AF10 fusion products in five patients and one AF10/CALM transcript. 17 The CALM/AF10 fusion protein is highly leukemogenic. Expression of CALM/AF10 leads to the development of an aggressive acute leukemia in a murine bone marrow transplant model 18 with a median latency of 110 days. Recently, it was reported that 40 --50% of the F1 generation of transgenic mice that express CALM/ AF10 under the control of the vav promoter developed acute leukemia with a median latency of 12 months. 19 However, comparatively little is known about the molecular mechanism of leukemogenesis of CALM/AF10. 20 Okada et al.
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reported that the H3K79 methyltransferase hDOT1L contributes to MLL --AF10-mediated leukemogenesis through its interaction with AF10. According to Okada et al., mistargeting of hDOT1L to the Hoxa9 locus has an important role in MLL-AF10-mediated leukemogenesis. In another experiment, Okada et al. knocked down CALM/AF10 in U937 cells using a vector-based RNA interference and later transplanted these cells into NOD/SCID mice. 22 In this experiment, it could be shown that hDOT1L contributes to CALM/AF10-mediated leukemic transformation by preventing nuclear export of CALM/AF10 and upregulation of the Hoxa5 gene through H3K79 methylation. Okada et al. demonstrated that CALM/AF10 fusion is both necessary and sufficient for leukemic transformation. We have recently reported that the CALM/AF10 fusion protein can greatly reduce global H3K79 methylation in both human and murine leukemic cells by disrupting the AF10-mediated association of hDOT1L with chromatin. 7 This reduction in global H3K79 methylation was linked to an increased genomic instability. 7 To elucidate the consequences of CALM/AF10 expression on gene regulation, Caudell et al. 19 analyzed cDNA from hematopoietic tissues (bone marrow, spleen and thymus) from healthy and leukemic CALM/AF10-positive mice by real-time RT-PCR (reverse transcriptase PCR). This experiment showed that Hoxa5, Hoxa7, Hoxa9, Hoxa10 and Meis1 (myeloid ecotropic viral integration site 1 homolog) were upregulated in both healthy and leukemic CALM/AF10 transgenic mice. 19 The upregulation of certain HOXA cluster genes, BMI1 (B lymphoma Mo-MLV insertion region 1 homolog) and HOX cofactor MEIS1 was also found in CALM/AF10-positive T-ALL patient samples. 23 To understand the consequence of CALM/AF10 on gene regulation in greater detail, we set out to identify differentially regulated genes in a larger data set of CALM/AF10-positive leukemias in comparison with several other subtypes of ALL, AML and CML (chronic myelogenous leukemia). We observed upregulation of HOX cluster genes and of four genes located close to break point in AF10 on chromosome 10 (10p12) (COMMD3 (COMM domain containing 3), BMI, DNAJC1 (DnaJ (Hsp40) homolog subfamily C member 1) and SPAG6 (sperm associated antigen 6)). Dik et al. 23 also noted this in their study that compared CALM/AF10+ T-ALL to CALM/AF10-T-ALL. Interestingly, we also find the murine homologs of these genes (except Spag6) upregulated in samples from a CALM/AF10 murine bone marrow transplantation model. 18 This finding strongly suggests that the upregulation of these genes is due the fusion protein itself and cannot be due to translocation-mediated positional effects. Gene set enrichment analysis (GSEA) shows that CALM/AF10 leukemias are characterized by deregulation of genes involved in DNA repair and chromatin modification and maintenance. Our findings add new insights into the molecular pathways that are involved in CALM/AF10-mediated leukemogenesis.
MATERIALS AND METHODS

Patient material
Patient cDNA or frozen bone marrow cells that were analyzed were provided by the Laboratory for Leukemia Diagnostics, Department of Medicine III, Großhadern, Ludwig Maximilians University, Munich, Germany; University Hospital S. Maria della Misericordia, Perugia, Italy; the Immunologic Marker Laboratory, Charité University Hospital, Berlin, Germany and from the department of Hematology/Oncology, Children's Hospital, Ludwig Maximilians-University, Munich, Germany. Frozen cells were thawed and washed once in phosphate buffered saline (PAN-Biotech GmbH, Mainz, Germany) (300 Â g at 4 1C for 5 min) before RNA extraction. Only leftover patient material was used in this analysis. The institutional review board of the University Hospital Munich has approved the use of leftover diagnostic samples for research projects in an anonymous fashion.
Primers
The primers used for the CALM/AF10 amplification and housekeeping gene expression in patient samples are described in Supplementary Table 2 . The primers used to assess the expression levels of the genes Bmi1, Spag6, Dnajc1, Commd3 and B2m in mice are listed in the Supplementary Table 3. Sequencing of CALM/AF10 transcripts PCR products were run on agarose gel and extracted from the gel with the QIAquick Gel Extraction Kit (QIAGEN GmbH, Hilden, Germany), and were cloned into pGEMT-easy (Promega, Manheim, Germany) and sequenced (ABI Prism Sequencing Kit, Foster City, CA, USA).
RNA extraction and cDNA synthesis (Reverse Transcriptase Reaction)
RNA from patient and mouse cells was extracted using the Trizol reagent (Invitrogen, Karlsruhe, Germany) following the manufacturer's instructions. For cDNA synthesis, all the reagents (SuperScript II Reverse Transcriptase, Oligo (dT) 12À18 primer, dNTP and DNaseI) and protocols used were purchased from Invitrogen (Life Technologies, Carlsbad, CA, USA). To avoid DNA contamination, the RNA was treated with DNaseI before cDNA synthesis. For reverse transcriptase reactions, 0.5--2 mg of total RNA was used.
Gene expression profiling
The RNA obtained was used for cDNA synthesis and microarray analysis, using the GeneChip System (Affymetrix, Santa Clara, CA, USA). The targets for GeneChip analysis were prepared according to the Expression Analysis Technical Manual provided by the manufacturer (Affymetrix, Santa Clara, CA, USA). Details are provided in the Supplementary methods section. 
Microarray data analysis
All the primary data files (.CEL files) were normalized together using an R statistical package implementation of the variance stabilization normalization algorithm (R version 2.8.1 and Bioconductor version 2.5) (R foundation for Statistical Computing, Vienna, Austria; Bioconductor Core team and developers, various countries). Data obtained from HGU133A and HGU133B chips were combined and were subsequently treated as HGU133 plus 2.0 arrays. Details of statistical approaches and packages used are outlined in the Supplementary section.
RESULTS
Identification and sequencing of CALM/AF10 transcripts in patient samples Patients with a t(10;11)(p12;q14) translocation (n ¼ 16) were tested by RT-PCR for the presence of CALM/AF10 fusion transcripts. All the patients with t(10;11) tested positive for the CALM/AF10 transcript. As the CALM/AF10 fusion gene was reported to be the most common fusion gene among patients with T-ALL with T-cell receptor gd rearrangement, 24 we tested a series of 29 T-ALL patients with T-cell receptor gd rearrangement for the presence of CALM/AF10 transcripts. Four patients (13.8%) were positive for the CALM/AF10 fusion transcript (Supplementary Table 1 ; patients 10--13).
Sequence analysis from all CALM/AF10-positive patient samples (n ¼ 20) revealed three break points in CALM (at nucleotide 1926, 2091 and 2064; accession no. NM_007166) and four break points in AF10 (at nucleotide 424, 589, 883 and 979; accession no. NM_004641) (Figure 1 ). In total, 11 of the 20 CALM/AF10-positive patient samples were also positive for the AF10/CALM transcript.
We did not observe a correlation between CALM/AF10 break points and leukemic subtypes, or between break points and treatment/survival outcome. Supplementary Table 1 summarizes the patient data.
Gene expression analysis of CALM/AF10 patients Some HOXA cluster genes are differentially expressed in CALM/AF10-positive samples. CALM/AF10 positive samples were compared with the different patients and controls in this study using Linear Models for Microarray Data (limma) package. First, CALM/AF10-positive patients were compared with every patient/ control group separately. The result of the separate comparisons (list of differentially regulated genes) was then summarized by adjusting for multiple hypothesis testing. The gene expression profiles of 10 CALM/AF10-positive samples were compared with the following leukemic and healthy samples: ALL (ALL; n ¼ 12), ALL with t(4;11)(q21;q23) rearrangement (ALL_MLL_AF4; n ¼ 11), AML with complex aberrant karyotype (AML_Comp.; n ¼ 10), AML with normal karyotype and FLT3-ITD (AML_nk_FLT3 þ ; n ¼ 10), AML with t(8;21)(q22;q22) (AML1_ETO; n ¼ 10), AML with t(15;17)(q21;q22) (PML_RARA; n ¼ 10), AML with inv(16)(p13q22) (CBFB_MYH11; n ¼ 10), AML with MLL rearrangement (AML_MLL; n ¼ 10), AML with normal karyotype and FLT3 negative (AML_nk_FLT3 --; n ¼ 12), ALL with t(9;22)(q34;q11) (ALL_Ph; n ¼ 10), CML (CML; n ¼ 10), normal bone marrow (nBM; n ¼ 10) and T-ALL (T_ALL; n ¼ 10). In this comparison, 233 probe sets were found to be statistically significantly differentially expressed (P-value o0.05; least F value of 15.19 after adjusting for multiple comparisons as described in the methods section) (Supplementary Table 4 ). One hundred and sixty (68.67%) probe sets were found to be upregulated in CALM/AF10 samples whereas 73 probe sets (31.33%) were downregulated. We observed that the homeobox gene MEIS1 and several HOX cluster genes (HOXA3, HOXA5, HOXA7, HOXA9 and HOXA10) were significantly upregulated in CALM/AF10-positive samples.
Genes located proximal to AF10 are upregulated in CALM/AF10 patients. We further analyzed the distribution of the differentially regulated genes across the genome. Interestingly, there is a small cluster of four genes (BMI1, COMMD3, DNAJC1 and SPAG6) adjacent and centromeric to the translocation breakpoint on chromosome 10 band p12. We observed that these genes were significantly upregulated in CALM/AF10-positive patients (Figure 2  and Supplementary Table 5) .
Genes located proximal to AF10 are also upregulated in a CALM/ AF10 murine bone marrow transplantation model. To assess whether the upregulation of these four genes is due to a position effect caused by the t(10;11)(p12;q14) translocation event or due to the direct regulation of these genes by the CALM/AF10 fusion protein, we conducted semiquantitative RT-PCR on leukemic cells from a murine CALM/AF10 bone marrow transplantation model. In this model, the CALM/AF10 fusion protein is expressed from an integrated retrovirus. Bmi1, Commd3 and Dnajc1 but not Spag6 were highly expressed in the primary leukemic bone marrow cells as well as in a cell line derived from the leukemic cells (Figure 3 ). In the mouse genome, Bmi1, Commd3 and Dnajc1 are syntenic and are located on chromosome 2. In contrast, Spag6 is located on mouse chromosome 16. As there is no translocation in this model, these results clearly show that the upregulation of Bmi1, Commd3 and Dnajc1 is not due to the t(10;11)(p12;p14) positional effect but rather as the consequence of the expression of the CALM/AF10 fusion gene, though the mechanism of regulation is not yet understood.
CALM/AF10 classifies with ALLs and shows strong similarity to ALL with MLL rearrangement. Using multivariate approach, we set out to classify the different leukemic samples based on their transcriptional pattern as observed by our microarray study. Our primary target was to assess which samples show similar transcription program to CALM/AF10-positive samples. We used MADE4, a bioconductor package that facilitates multivariate analysis of microarray gene expression data. In our current study, we chose the top two functions and drew a bi-plot of the 14 different leukemic groups and nBM (Figure 4) . We observed that the samples were neatly classified into leukemias of myeloid (right section of the plot) and lymphoid (left section of the plot) origin. Additionally, CALM/AF10 samples were grouped closer to the ALL subgroup: T_ALL, ALL_MLL_AF4 and other ALL samples. nBM samples did not show strong overlap with any of the leukemic samples.
GSEA. We performed GSEA analysis to investigate whether the deregulated genes in the CALM/AF10-positive samples were clustered in certain functional categories.
Leading edge analysis showed that the most significantly upregulated genes in the CALM/AF10-positive samples belong to the following processes and pathways (gene sets): 'chromatin assembly and architecture', 'chromatin remodelling' and 'DNA replication and repair' (Figure 5a and Supplementary Figure 1) . In fact, 8 out of the top 20 gene sets containing genes upregulated in CALM/AF10 (40%) belonged to these three processes/pathways (Figures 5 and 6a; Supplementary Figures 1 --3 ; Supplementary  Tables 6 and 7) .
The genes that were downregulated in CALM/AF10-positive leukemias were enriched in very different gene sets compared with the upregulated genes. These gene sets included, for example, 'extracellular region', 'angiogenesis' and 'tissue development' (Figure 6a and b and Supplementary Figure 2) . The overlap between the enriched gene sets for the downregulated genes was not as strong as observed for the upregulated genes.
DISCUSSION
We were able to analyse samples from 20 CALM/AF10-positive leukemic patients. The patients were children or young adults, between 5 and 46 years old (average age: 22). A similar age distribution was reported in other studies of CALM/AF10 patients. 25 --27 All leukemias were acute leukemias, which were undifferentiated or of lymphoid or myeloid lineage. We did not see any obvious correlation between age, diagnosis and the location of the break points in CALM or AF10 in our patients.
Sixteen of these patients were identified as CALM/AF10-positive based on chromosomal analysis. We also identified four CALM/AF10-positive cases in a series of 29 patients with T-ALL with T-cell receptor gd rearrangement, confirming a previous report of the high prevalence of CALM/AF10 among this group of leukemias. 24 The reciprocal AF10/CALM transcript was identified in only 11 of the 20 patients emphasizing the fact that the CALM/AF10 fusion is the critical event in these leukemias. Genes   SMARCA5  ASF1A  RSF1  NAP1L1  MRE11A  CHAF1A  NAP1L4  RAD50  SET  SOD1  ARID1A  HELLS  XRCC6  RAD51  RAD21  HMGB1  SMARCD1  SMARCC1  SMARCC2  RUVBL2  ATRX  MBNL1  SIRT5 Genes   AZU1  INHBA  IL8  PF4  PLOD1  CTGF  UGCG  EREG  STAB1  RNH1  COL17A1  ELA2  MYH9 
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We were able to analyze the gene expression profile for 10 of our 20 CALM/AF10 patients. The gene expression profile of the CALM/AF10-positive patients was compared with the profile of 12 other leukemia subtypes (ALL, ALL with t(4;11)(q21;q23) rearrangement, AML with complex aberrant karyotype, AML with normal karyotype and FLT3-ITD, AML with t(8;21)(q22;q22), AML with t(15;17)(q21;q22), AML with inv(16)(p13q22), AML with MLL rearrangement, AML with normal karyotype and FLT3 negative, ALL with t(9;22)(q34;q11), CML and T-ALL) as well as from nBM samples.
CALM/AF10 and MLL fusion gene-positive leukemias are similar in their gene expression patterns We observed differential expression of the homeobox gene MEIS1 and several clustered HOX genes (HOXA3, HOXA5, HOXA7, HOXA9 and HOXA10) in CALM/AF10-positive leukemias when compared with several other leukemic subgroups. Dik et al. 23 also observed differential regulation of HOXA5, HOXA9 and HOXA10, but not of HOXA3 or HOXA7 by comparing six CALM/AF10 T-ALL with 17 T-ALL CALM/AF10-negative patients using gene expression arrays.
The involvement of HOX genes in acute leukemias has been widely reported.
28 --32 Ayton and Cleary 28 showed the dependence of MLL fusion proteins on Hoxa9 and Hoxa7 to transform myeloid progenitors in a mouse transplantation model. Soulier et al. 31 observed high expression of some HOXA genes in T-ALL patients, suggesting that HOXA upregulation is a common feature of CALM/ AF10 and MLL leukemias. These findings and our results suggest that CALM/AF10-positive leukemias are closely related to MLL fusion gene-positive leukemias.
In addition, several homeoproteins are involved in neoplasia. MEIS1, a gene that encodes a homeobox protein belonging to the 'three amino acid loop extension' family of homeodomaincontaining proteins, was also observed to be differentially regulated in CALM/AF10-positive leukemias. Interestingly, Meis1 was shown to collaborate with Hoxb3 in leukemogenesis and accelerate the onset of HOXA-induced leukemias, as well as to reduce the latency of leukemias in mice transplanted with cells retrovirally expressing the fusion gene NUP98-HOXD13. 32, 33 Considering the similar expression pattern of HOX genes observed in MLL-and in CALM/AF10-positive leukemias, the elevated expression of MEIS1 again suggests similar leukemogenic mechanisms in CALM/AF10 and MLL fusion gene-driven leukemias.
The similarity of CALM/AF10-positive leukemias to leukemias with MLL rearrangements is also evident in the global expression pattern of the current data set based on the findings of the between-group analysis ( Figure 4) . As stated in Results section, CALM/AF10-positive samples showed strong similarity/overlap with T_ALL and ALL with MLL rearrangements. This result suggests that CALM/AF10 and MLL-AF4, and potentially other MLL fusions, may have similar transcriptional programs and this could be further investigated in future studies.
Genes located proximal to AF10 are differentially regulated in CALM/AF10-positive samples We were able to confirm the observation of Dik et al. 34 that genes located proximal to the chromosome 10 break point of CALM/AF10 translocations (DNAJC1, COMMD3, BMI1 and SPAG6) are highly expressed in CALM/AF10 patients. One distinction of note is that Dik et al. observed this phenomenon in a comparison of CALM/ AF10 þ T-ALL with CALM/AF10 À T-ALL cases, whereas we compared CALM/AF10 þ leukemias with several other leukemia subtypes and normal bone marrow. As DNAJC1, COMMD3, BMI1 and SPAG6 are located centromeric to the 10p12 break point, it could be speculated that the overexpression of these four genes might be as a result of a positional effect caused by the action of the strong CALM promoter or enhancer in the t(10;11)(p12;q14) translocation. To test this hypothesis, we analyzed the expression levels of these four genes in the blasts from a murine leukemia model in which the CALM/AF10 fusion gene is expressed from an integrated retrovirus and in a cell line derived from this model. Bmi1, Commd3 and Dnajc1 but not Spag6 were found to be highly expressed in these cells, suggesting that these genes are deregulated as a consequence of the CALM/AF10 fusion protein and not due to the chromosomal translocation. Interestingly, in the mouse genome, Bmi1, Commd3 and Dnajc1 are syntenic on chromosome 2, whereas Spag6 is located on chromosome 16.
The relevance of these genes to the onset or progression of CALM/AF10-mediated leukemia is not understood. BMI1 was first identified by provirus tagging in Em-myc transgenic mice as a cooperating oncogene in pre-B cell lymphomagenesis. 35 It has to be stressed that high expression levels of BMI1 was quite unique to CALM/AF10-positive leukemias. In addition, the overexpression of BMI1 has recently been shown to be essential for self-renewal of hematopoietic stem cells 36, 37 and is associated with certain types of cancer. 38, 39 Little is known about the role of the other genes in malignancies. Loss of COMMD3 has recently been shown to be relevant in low-grade B-cell lymphomas that had high levels of genomic instability. 40 Interestingly, Ferreira et al. observed gain of BMI1 in these lymphomas, strengthening our observation of the potential link between these two genes.
GSEA shows that DNA repair and chromatin assembly/disassembly genes are highly expressed in CALM/AF10-positive samples One way to extract useful information from the long lists of differentially regulated genes is to determine whether they belong to a certain biological process or pathway. Such an approach reveals potentially perturbed pathways.
To understand the pathways and/or cellular processes affected in CALM/AF10 leukemias, we carried out GSEA ( Figures 5, 6a and b ; Supplementary Figures 1 and 2; Supplementary Tables 6 and 7) . The GSEA method derives its power by focusing on gene sets, that is, groups of genes that share a common biological function or regulation, or are located close to each other on the chromosome. 41 Our analysis revealed that genes involved in chromatin assembly and disassembly, establishment and or maintenance of chromatin architecture, and DNA repair showed a strong positive correlation with CALM/AF10 leukemias in comparison with other patient classes.
There are a number of reports that stress the role of DNA repair and chromatin remodelling in genomic stability. Recent studies have shown that the cellular responses towards DNA damage, such as cell cycle arrest, DNA repair, chromatin remodelling and apoptosis are finely coordinated. 42, 43 There is some evidence that suggests that chromatin remodelling complexes are important players in DNA double-strand break repair. 44 There are reports that discuss the role of chromatin structure, chromatin dynamics and nonrandom global genome organization as key factors in genome maintenance 45 , and the interplay between DNA repair proteins and chromatin marks at a unique double-strand break has been shown in vivo. 46 Our group has also recently shown that there is indeed increased chromosomal instability in CALM/AF10-positive leukemias and that chromosomal instability associated with global epigenetic alterations most likely contributes to malignant transformation in certain leukemias. 7 The CALM/AF10 fusion protein is capable of interacting with the histone H3 lysine 79 (H3K79)-specific methyltransferase hDOT1L through its AF10 portion. CALM/AF10 greatly reduces global H3K79 methylation in both human and murine leukemic cells by disrupting the AF10-mediated association of hDOT1L with chromatin. We have also observed that patients with a CALM/AF10 fusion had more secondary chromosomal aberrations. 7 These findings suggest that chromosomal instability associated with global epigenetic alterations contributes to malignant transformation in certain leukemias.
Angiogenesis, tissue formation and extracellular matrix are negatively correlated to CALM/AF10 leukemias When we analyzed the pathways that were enriched by genes that are expressed at lower levels in CALM/AF10 samples, it was noted that cellular processes like angiogenesis, tissue formation and extracellular matrix formation were significantly affected.
A role of angiogenesis in leukemia and especially in solid malignancies has been well described. Some of these reports provide evidence of increased angiogenesis. 47 --49 As our data show that angiogenesis genes are not highly expressed in CALM/ AF10 samples (that is, positively correlated with the other leukemias), we speculate that this phenomenon is unique to leukemias harbouring the CALM/AF10 translocation.
Tissue formation and differentiation in conjunction with cell-tocell signalling is crucial for the development of multicellular organisms. The downregulation of genes involved in tissue formation and differentiation in CALM/AF10 samples suggest that these leukemias might have a more primitive differentiation stage than other leukemia subtypes and normal bone marrow. The differentiation process not only requires the expression of tissuespecific genes but also the downregulation of genes that inhibit this process. It is known that sustained HoxA7 expression disturbs the regulation of cell adhesion and migration on fibronectin during early differentiation. 50 In this context it should be noted that HOXA7 is upregulated in our CALM/AF10 samples.
We report on 20 patients with acute leukemia and the t(10;11)(p12;q14) translocation that leads to the formation of the CALM/AF10 fusion gene. We aimed at understanding the consequence of CALM/AF10 on the gene expression pattern in 10 patients compared with a group of 125 patients with different types of acute leukemia and 10 normal bone marrow samples. Our analysis shows that the level of expression of HOXA cluster genes is statistically significantly higher in CALM/AF10 leukemias. Interestingly, genes that are located centromeric to AF10 on chromosome 10 in CALM/AF10-positive patients (BMI1, COMMD3, DNAJC1 and SPAG6) are highly expressed in CALM/AF10 samples. We could demonstrate that the differential regulation of these genes is not as a consequence of the translocation but as a result of the expression of the CALM/AF10 fusion protein. We showed this by analyzing a murine CALM/AF10 retroviral bone marrow transplantation model that expresses the fusion gene but lacks the t(10;11)(p12;q14) translocation. Gene ontology analysis using GSEA revealed that genes playing a role in genomic stability and tissue formation are deregulated in CALM/AF10 leukemias. These findings suggest that the impact of the fusion gene in genomic stability, DNA repair and differentiation might create a suitable platform for additional genetic lesions, which would then act synergistically with CALM/AF10 itself to promote leukemogenesis.
